This site is intended only for healthcare professionals resident in India
Menu
Close
Menu
Close
ZINFORO® (ceftaroline fosamil) achieved high clinical cure rate and showed evidence of rapid response with cSSTI
Overall, 74% of ZINFORO® (ceftaroline fosamil)- treated patients achieved clinical stability and improvement in symptoms by Day 3.1,*
Header | ||
---|---|---|
Header | Header | Header |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
Content | Content | Content |
ZINFORO® (ceftaroline fosamil) was associated with a trend towards early clinical response when compared with vancomycin + aztreonam at Day 3.1
*ZINFORO® (ceftaroline fosamil) was associated with a non-statistical significant early clinical response defined by the cessation of lesion spread and absence of fever.1
cSSTI, complicated skin and soft tissue infection; MRSA, methicillin-resistant Staphylococcus aureus; q12h, every 12 hours.
Reference:
Please click the Prescribing Information link to view the safety and adverse events information of ZINFORO®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.
PP-ZFO-IND-0417 June 2022
Fifth-generation cephalosporin with broad coverage
Simple dosing with a flexible infusion time
Safety profile consistent with other cephalosporins
ZINFORO® in the treatment of CAP and cSSTI
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.
Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.
Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered Medical Practitioner*, please visit
https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.